-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Qg4RYpmjz6IS+q2IMw84hJF1BQ66zc5mR1tdQwUUjFjCB3A1sart/glRkoaH7qhk /+A/vW06li1tgZ9AKZrscQ== 0001104659-04-039543.txt : 20041214 0001104659-04-039543.hdr.sgml : 20041214 20041214164203 ACCESSION NUMBER: 0001104659-04-039543 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20041208 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20041214 DATE AS OF CHANGE: 20041214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEPHALON INC CENTRAL INDEX KEY: 0000873364 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232484489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19119 FILM NUMBER: 041201932 BUSINESS ADDRESS: STREET 1: 145 BRANDYWINE PKWY CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 6103440200 MAIL ADDRESS: STREET 1: 145 BRANDYWINE PARKWAY CITY: WEST CHESTER STATE: PA ZIP: 19380 8-K 1 a04-14724_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported)  December 8, 2004

 

Cephalon, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

 

 

 

Delaware

 

0-19119

 

23-2484489

(State or Other Jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification No.)

 

 

 

 

 

145 Brandywine Parkway

 

 

West Chester, Pennsylvania

 

19380

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code  (610) 344-0200

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

                ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

                ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

                ¨ Pre-commencement pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

                ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 


 

Item 1.01               Entry into a Material Definitive Agreement.

 

                On December 8, 2004, the registrant’s wholly-owned subsidiary, Cephalon France (S.A.S), entered into a master asset purchase agreement with Sanofi-Synthelabo France (SA).  Under the agreement, Cephalon France will purchase from Sanofi-Synthelabo France all of its rights to the promotion, distribution and sale in France and French overseas territories of NAXY® and MONO-NAXY® (clarithromycin), an antibiotic, for approximately €31 million (approximately US$41 million).  Abbott France holds the underlying rights to the product, which were first licensed to Sanofi-Synthelabo France in 1991.  Abbott France manufactures clarithromycin and also promotes, distributes and sells clarithomycin under the trademark ZECLAR®  in the French market.  NAXY® is co-marketed with Abbott’s ZECLAR® in France.

 

                Closing of this transaction is subject to the receipt of final approval of the European Commission, which has required the divestiture of this product by Sanofi-Synthélabo France as part of the acquisition of Aventis by Sanofi-aventis.

 

 

 


 

SIGNATURES

 

 

                Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CEPHALON, INC.

 

 

 

 

Date: December 14, 2004

By: 

/s/ J. Kevin Buchi

 

 

J. Kevin Buchi
Senior Vice President & Chief Financial Officer

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----